P. Richardson

Articles by P. Richardson

In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma

ByR. J. Buckstein,K. Imrie,D. Spaner,L. Bordeleau,T. Tompkins,E. Iakhnina,N. Pennell,A. Coovadia,M. Reis,K. Hewitt,P. Richardson,A. Lima,J. B. Robinson,M. Lim,B. Ordonez-Perez,N. L. Berinstein

March 1st 2000

We previously reported that “in vivo purging” with rituximab (Rituxan) during stem-cell collection is safe and does not adversely affect engraftment. We now report on our transplant experience with rituximab. From June 1998 to December

Latest Updated Articles

In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma
March 1st 2000

P. Richardson

Articles by P. Richardson

In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma

Latest Updated Articles

Trending on CancerNetwork

Revolutionizing Oncology in the Digital Age: Effects on Health Care Providers

3 Things You Should Know About Frontline and Maintenance Therapy for HER2+ Metastatic Breast Cancer

How Do You Choose The Right Frontline Therapy in CLL Care?

3 Things You Should Know About Using Selective Estrogen Receptor Degraders in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

From Conference to Practice: Top 5 Takeaways From EHA 2026